X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (22) 22
humans (21) 21
female (17) 17
male (17) 17
middle aged (16) 16
oncology (15) 15
adult (13) 13
aged (13) 13
cancer (12) 12
chemotherapy (10) 10
aged, 80 and over (9) 9
analysis (9) 9
surgery (9) 9
capecitabine (8) 8
5-fluorouracil (7) 7
radiotherapy (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
care and treatment (6) 6
fluorouracil - adverse effects (6) 6
medicine & public health (6) 6
stomach cancer (6) 6
toxicity (6) 6
dihydrouracil dehydrogenase - genetics (5) 5
fluorouracil (5) 5
follow-up studies (5) 5
neoplasm staging (5) 5
prognosis (5) 5
stomach neoplasms - pathology (5) 5
surgical oncology (5) 5
adenocarcinoma - mortality (4) 4
adenocarcinoma - therapy (4) 4
antimetabolites, antineoplastic - adverse effects (4) 4
chemoradiation (4) 4
chemoradiotherapy (4) 4
clinical trials (4) 4
dihydropyrimidine dehydrogenase (4) 4
fluorouracil - administration & dosage (4) 4
gastrectomy (4) 4
netherlands (4) 4
patients (4) 4
phase-iii trial (4) 4
research (4) 4
stomach neoplasms - mortality (4) 4
stomach neoplasms - therapy (4) 4
survival (4) 4
treatment outcome (4) 4
5‐fluorouracil (3) 3
adenocarcinoma (3) 3
adenocarcinoma - pathology (3) 3
antimitotic agents (3) 3
antineoplastic agents (3) 3
cancer patients (3) 3
cancer therapies (3) 3
capecitabine - adverse effects (3) 3
deoxycytidine - administration & dosage (3) 3
deoxycytidine - analogs & derivatives (3) 3
dihydrouracil dehydrogenase - metabolism (3) 3
efficacy (3) 3
fluoropyrimidines (3) 3
fluorouracil - analogs & derivatives (3) 3
gastric cancer (3) 3
gastroenterology & hepatology (3) 3
genotype (3) 3
hematology, oncology and palliative medicine (3) 3
lymph-node dissection (3) 3
neoplasm recurrence, local - mortality (3) 3
neoplasm recurrence, local - pathology (3) 3
neoplasms - drug therapy (3) 3
nuclear radiation (3) 3
oncology, experimental (3) 3
oxaliplatin (3) 3
pharmacology & pharmacy (3) 3
quality of life (3) 3
safety (3) 3
survival rate (3) 3
therapy (3) 3
thymidylate synthase - genetics (3) 3
young adult (3) 3
abridged index medicus (2) 2
adenocarcinoma - secondary (2) 2
adjuvant chemotherapy (2) 2
alleles (2) 2
antimetabolites, antineoplastic - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
bevacizumab (2) 2
capecitabine - administration & dosage (2) 2
carboplatin (2) 2
carcinoma (2) 2
carcinoma, squamous cell - therapy (2) 2
carcinomas (2) 2
cats (2) 2
chemoradiotherapy, adjuvant (2) 2
cisplatin (2) 2
clinical-practice guidelines (2) 2
clinical-relevance (2) 2
clinical-trial (2) 2
colorectal cancer (2) 2
colorectal-cancer (2) 2
combined modality therapy (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9980, pp. 1843 - 1852
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1639 - 1650
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2013, Volume 85, Issue 5, pp. e201 - e207
Purpose Newer radiation techniques, and the application of continuous 5-FU exposure during radiation therapy using oral capecitabine may improve the treatment... 
Radiology | Hematology, Oncology and Palliative Medicine | 5-FLUOROURACIL | EFFICACY | ONCOLOGY | CHEMORADIATION | RANDOMIZED-TRIAL | TOXICITY | RADIOTHERAPY | ADVANCED RECTAL-CANCER | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | CHEMOTHERAPY | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Capecitabine | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Fatigue - etiology | Male | Radiotherapy, Intensity-Modulated - adverse effects | Feasibility Studies | Fluorouracil - administration & dosage | Fluorouracil - adverse effects | Anus Neoplasms - therapy | Pain - etiology | Adult | Deoxycytidine - adverse effects | Dose Fractionation | Female | Radiodermatitis - etiology | Glutathione S-Transferase pi - genetics | Mitomycin - adverse effects | Fluorouracil - analogs & derivatives | Administration, Oral | Cytidine Deaminase - genetics | Deoxycytidine - administration & dosage | Radiotherapy, Intensity-Modulated - methods | Carcinoma, Squamous Cell - therapy | Anus Neoplasms - pathology | Lymphatic Metastasis | Combined Modality Therapy - adverse effects | Polymorphism, Genetic | Maximum Tolerated Dose | Diarrhea - etiology | Aged | Combined Modality Therapy - methods | Infusions, Intravenous | Mitomycin - administration & dosage | Deoxycytidine - analogs & derivatives | Dihydrouracil Dehydrogenase (NADP) - genetics | Sects | Care and treatment | Mitomycin | Nuclear radiation | Analysis | Radiotherapy | Cancer | Index Medicus | PATIENTS | DERMATITIS | LYMPH NODES | SAFETY | FATIGUE | MITOMYCIN | RADIATION DOSES | IRRADIATION | PAIN | CARCINOMAS | RADIOLOGY AND NUCLEAR MEDICINE
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2014, Volume 88, Issue 3, pp. 624 - 629
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 09/2016, Volume 82, Issue 3, pp. 706 - 716
Journal Article
Annals of Surgical Oncology, ISSN 1068-9265, 2013, Volume 20, Issue 9, pp. 2937 - 2943
Journal Article
British Journal of Cancer, ISSN 0007-0920, 04/2017, Volume 116, Issue 11, pp. 1415–1424 - 1424
BACKGROUND: We investigated the predictive value of dihydropyrimidine dehydrogenase (DPD) phenotype, measured as pretreatment serum uracil and dihydrouracil... 
5-fluorouracil | toxicity | capecitabine | uracil | dihydropyrimidine dehydrogenase | fluoropyrimidines | Fluoropyrimidines | Dihydropyrimidine dehydrogenase | Capecitabine | Toxicity | Uracil | RATIOS | DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY | CHEMOTHERAPY | PLASMA | COLORECTAL-CANCER PATIENTS | PHARMACOKINETICS | ONCOLOGY | DIHYDROURACIL | DPD DEFICIENCY | DPYD VARIANTS | Predictive Value of Tests | Capecitabine - metabolism | Prospective Studies | Humans | Middle Aged | Male | Young Adult | Dihydropyrimidine Dehydrogenase Deficiency - complications | Neoplasms - blood | Dihydropyrimidine Dehydrogenase Deficiency - genetics | Fluorouracil - adverse effects | Drug-Related Side Effects and Adverse Reactions - genetics | Aged, 80 and over | Pharmacogenomic Variants | Adult | Female | Fluorouracil - metabolism | Uracil - blood | Thymidylate Synthase - metabolism | Genotype | Hospitalization | Biomarkers - blood | Pharmacogenomic Testing | Thymidylate Synthase - genetics | Neoplasms - drug therapy | Phenotype | Capecitabine - adverse effects | Alleles | Antimetabolites, Antineoplastic - adverse effects | Leukocytes, Mononuclear - enzymology | Aged | Drug-Related Side Effects and Adverse Reactions - mortality | Dihydrouracil Dehydrogenase (NADP) - metabolism | Dihydrouracil Dehydrogenase (NADP) - genetics | Uracil - analogs & derivatives | Index Medicus | Translational Therapeutics
Journal Article
International Journal of Cancer, ISSN 0020-7136, 05/2019, Volume 144, Issue 9, pp. 2347 - 2354
Journal Article
Nature, ISSN 0028-0836, 2019, Volume 570, Issue 7761, pp. 385 - 389
Journal Article
Journal Article